Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Lanabecestat termination: another blow for BACE inhibitors
  2. EULAR 2018: Focus on infliximab biosimilars in rheumatoid arthritis
  3. Pfizer’s blockbuster drug Lyrica comes off-patent in 2018
  4. Report: Gene therapies may see success and regulatory oncology updates
  5. Deals and M&As this week: Alexion Pharmaceuticals, Recipharm, AstraZeneca

Latest Content

Lanabecestat termination: another blow for BACE inhibitors

After the disappointing failures of highly anticipated anti-amyloid pipeline drugs, such as Pfizer/Johnson & Johnson’s bapineuzumab and Eli Lilly’s solanezumab, the focus of research in Alzheimer’s has increasingly turned to beta-secretase (BACE) inhibitors. Unlike the injectable monoclonal antibodies, the BACE inhibitors are oral small molecules.

EULAR 2018: Focus on infliximab biosimilars in rheumatoid arthritis

On June 14th, Biocad presented Week 14 results on the safety and efficacy of BCD-055 (infliximab biosimilar) from the ongoing Phase III LIRA clinical trial. The international, multicenter, double-blind, placebo-controlled trial randomised (2:1) 426 adult patients with active rheumatoid arthritis (RA) to receive BCD-055 or infliximab innovator for 54 weeks both at a dose of 3mg/kg. At Week 14, 71.6% of patients receiving BCD-055 compared with 67.9% of patients receiving Remicade achieved American College of Rheumatology 20% improvement criteria (ACR20) (p=0.587).

The ten most promising cancer drugs being trialled

To meet rising demand, companies worldwide are striving to develop cost-effective and innovative therapies for a wide variety of cancer types. lists some of the most promising oncology drugs that are currently undergoing late-stage clinical trials.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top